C Goh1, L Churilov, P Mitchell, R Dowling, B Yan. 1. Department of Radiology, Neurointervention Service, Comprehensive Stroke Centre, Royal Melbourne Hospital, and Department of Mathematics and Statistics, University of Melbourne, Melbourne, Australia.
Abstract
BACKGROUND AND PURPOSE: Antiplatelet therapy is associated with decreased ischemic events after neurointerventional procedures. Antiplatelet resistance negates the protective effects of antiplatelet medication, leading to a higher incidence of ischemic events. A possible link between antiplatelet hyper-response and increased hemorrhagic complications has been inadequately investigated. We aimed to examine the correlation between antiplatelet hyper-response and the risk of hemorrhagic complications. MATERIALS AND METHODS: Patients who were treated with antiplatelet medications and underwent neurointerventional procedures were prospectively recruited. We collected the following data: demographics, vascular risk factors, antiplatelet and anticoagulation treatment, antiplatelet responsiveness, coagulation profile, and hemorrhagic complications. P2Y12 receptor-mediated platelet inhibition was tested by using the VerifyNow assay device. The primary end points were postprocedural major and minor hemorrhagic complications. Receiver operator characteristic analysis was used to evaluate the percentage of platelet inhibition as a diagnostic tool for bleeding events. The association between hemorrhage and percentage of platelet inhibition was investigated by using logistic regression modeling. RESULTS: Forty-seven patients were enrolled. The mean age was 56±12 years, and 28% were men. Ten patients (21.3%) developed hemorrhagic complications. Clopidogrel response was higher in patients with a major bleeding complication compared with those with minor or no bleeding (median, 94% versus 24% platelet inhibition; P=.0084). Of the 7 patients (14.9%) defined as hyper-responders with ≥72% platelet inhibition, 42.8% had a major bleeding complication. CONCLUSIONS: Hyper-response to clopidogrel is associated with increased risk of hemorrhagic complications. Larger studies are urgently needed to validate a clinically useful threshold to define clopidogrel hyper-response and to examine the clinical effects of antiplatelet dosage adjustment.
BACKGROUND AND PURPOSE: Antiplatelet therapy is associated with decreased ischemic events after neurointerventional procedures. Antiplatelet resistance negates the protective effects of antiplatelet medication, leading to a higher incidence of ischemic events. A possible link between antiplatelet hyper-response and increased hemorrhagic complications has been inadequately investigated. We aimed to examine the correlation between antiplatelet hyper-response and the risk of hemorrhagic complications. MATERIALS AND METHODS:Patients who were treated with antiplatelet medications and underwent neurointerventional procedures were prospectively recruited. We collected the following data: demographics, vascular risk factors, antiplatelet and anticoagulation treatment, antiplatelet responsiveness, coagulation profile, and hemorrhagic complications. P2Y12 receptor-mediated platelet inhibition was tested by using the VerifyNow assay device. The primary end points were postprocedural major and minor hemorrhagic complications. Receiver operator characteristic analysis was used to evaluate the percentage of platelet inhibition as a diagnostic tool for bleeding events. The association between hemorrhage and percentage of platelet inhibition was investigated by using logistic regression modeling. RESULTS: Forty-seven patients were enrolled. The mean age was 56±12 years, and 28% were men. Ten patients (21.3%) developed hemorrhagic complications. Clopidogrel response was higher in patients with a major bleeding complication compared with those with minor or no bleeding (median, 94% versus 24% platelet inhibition; P=.0084). Of the 7 patients (14.9%) defined as hyper-responders with ≥72% platelet inhibition, 42.8% had a major bleeding complication. CONCLUSIONS: Hyper-response to clopidogrel is associated with increased risk of hemorrhagic complications. Larger studies are urgently needed to validate a clinically useful threshold to define clopidogrel hyper-response and to examine the clinical effects of antiplatelet dosage adjustment.
Authors: K M Musallam; K Charafeddine; A Bitar; M Khoury; S Assaad; J Beresian; S Alam; A T Taher Journal: Int J Lab Hematol Date: 2010-11-03 Impact factor: 2.877
Authors: Dániel Aradi; András Komócsi; András Vorobcsuk; Orsolya Rideg; Margit Tokés-Füzesi; Tamás Magyarlaki; Iván Gábor Horváth; Victor L Serebruany Journal: Am Heart J Date: 2010-09 Impact factor: 4.749
Authors: Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati Journal: Circulation Date: 2010-01-18 Impact factor: 29.690
Authors: Jaapjan D Snoep; Marcel M C Hovens; Jeroen C J Eikenboom; Johanna G van der Bom; J Wouter Jukema; Menno V Huisman Journal: Am Heart J Date: 2007-08 Impact factor: 4.749
Authors: Christoph Varenhorst; Stefan James; David Erlinge; Oscar O Braun; John T Brandt; Kenneth J Winters; Joseph A Jakubowski; Sylvia Olofsson; Lars Wallentin; Agneta Siegbahn Journal: Am Heart J Date: 2009-02-06 Impact factor: 4.749
Authors: J E Delgado Almandoz; B M Crandall; J M Scholz; J L Fease; R E Anderson; Y Kadkhodayan; D E Tubman Journal: AJNR Am J Neuroradiol Date: 2013-07-04 Impact factor: 3.825
Authors: Min Soo Kim; Kyung Il Jo; Je Young Yeon; Jong Soo Kim; Keon Ha Kim; Pyoung Jeon; Seung Chyul Hong Journal: Neuroradiology Date: 2016-10-18 Impact factor: 2.804
Authors: M Lin; M Todaro; J Chan; L Churilov; W S Zhu; S Ramdave; P J Mitchell; R J Dowling; P Kwan; B Yan Journal: AJNR Am J Neuroradiol Date: 2015-09-03 Impact factor: 3.825